Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: GlobalData
$125.00
Provider: New Constructs, LLC
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

ImmunoGen Inc announces preclinical findings for IMGN779


Monday, 16 Jun 2014 06:30am EDT 

ImmunoGen Inc:Disclosed for first time preclinical data for IMGN779.IMGN779 is a novel, CD33-targeting, DNA-alkylating ADC that is potential treatment for acute myeloid leukemia (AML).Despite good initial responses to existing therapies, many AML patients relapse, driving the need for new treatment options.IMGN779 is ADC designed to selectively target and kill AML cells, including leukemic stem cells, while sparing normal cells.IMGN779 utilizes DGN462, one of company's new DNA-acting payload agents.In preclinical findings reported at EHA, IMGN779 demonstrated potent, targeted activity against primary AML patient cells in vitro.IMGN779 can selectively kill leukemic cells (blasts) while sparing normal hematopoietic (blood) stem cells.IMGN779 was found to be highly active against human AML xenografts in vivo, demonstrating potent and targeted activity.IMGN779 was well tolerated without delayed toxicity in animal models.IMGN779 is on track to become the company's next wholly owned clinical-stage compound.ImmunoGen is preparing to submit the IMGN779 IND in mid-2015. 

Company Quote

6.11
-4.74 -43.69%
19 Dec 2014